The era of multigene panels comes? The clinical utility of Oncotype DX and MammaPrint by Xin, Ling et al.
Articles © The authors   |   Journal compilation © World J Oncol and Elmer Press Inc™   |   www.wjon.org
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
34
Review World J Oncol. 2017;8(2):34-40
ressElmer 
The Era of Multigene Panels Comes? The Clinical Utility of 
Oncotype DX and MammaPrint
Ling Xina, b, Yin-Hua Liua, Tracey A. Martinb, c,  
Wen G. Jiangb
Abstract
The AJCC Cancer Staging Manual, eighth edition published in late 
2016, will become the new global guideline for cancer diagnosis and 
treatment from January 1, 2018. The new edition for the tumor stag-
ing system has numerous updates, including building up the prognos-
tic stage group of tumors for the first time and adding a large number 
of non-anatomical factors into the prognostic evaluation. Oncotype 
DX and MammaPrint are two of the genomic predictors that will be 
part of routine clinical practice in the future. Numerous studies have 
proved the clinical utility of multigene panels in predicting clinical 
outcome and treatment response. Here we present our review of the 
studies on these multigene panels and their application to breast can-
cer.
Keywords: Breast cancer; Multigene panel; Oncotype DX; Mam-
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Introduction
In 2013, the 13th St Gallen Panel recommended that gene ex-
pression panels be used to identify patients with good clinical 
outcome, which affirmed the value of multigene assays in 
clinical management among patients of luminal type breast 
cancer [1]. Two available tests, Oncotype DX and Mam-
maPrint, have exhibited good metric performances in the 
prediction of prognosis and treatment benefit of early-stage 
breast cancer and these genomic predictors are in routine 
clinical practice in some areas. Multigene expression-based 
assays used to analyze an array of prognostic biomarkers 
have been shown to help direct treatment decisions, which 
have become part of the AJCC Prognostic Stage Group de-
scribed by AJCC Cancer Stage Manual, the eighth edition in 
late 2016 [2]. We will review Oncotype DX and MammaPrint 
to discuss their current status and limitation in clinical prac-
tice.
Oncotype DX (Recurrence Score (RS))
Oncotype DX is performed on RNA extracted from formalin-
fixed paraffin-embedded tumor tissue, using quantitative real-
time reverse transcriptase polymerase chain reaction (qRT-
PCR). It contains a set of five reference genes (ACTB, GAPDH, 
GUS, RPLPO and TFRC) and 16 cancer-related genes. The RS 
is the result of a mathematical formula of the weighted expres-
sion of each gene, ranging from 0 to 100. The cutoff points are 
divided into three categories: low risk (RS < 18), intermediate 
risk (RS 18 - 30), and high risk (RS > 31). The RS has been 
proved to be a predictor of 10-year distant recurrence for early 
breast cancer through NSABP B-14 in multivariate analyses 
including age, tumor size, tumor grade, estrogen receptor (ER) 
status and HER2 status [3]. Furthermore, patients with low or 
intermediate RS had large improvements in disease-free sur-
vival (DFS) if treated with tamoxifen (TAM), which indicated 
that RS was helpful in evaluating treatment response to endo-
crine therapy in early breast cancer. Habel et al [4] conducted 
a case-control study among women with ER-positive, node-
negative breast cancer treated with TAM and compared these 
with untreated patients. The RS was associated with the risk of 
breast cancer death in both groups (P = 0.003 and P = 0.03). 
Thus, the RS was strongly related to long-term mortality of 
breast cancer among ER-positive breast cancer patients treated 
with endocrine therapy.
Paik et al [3] not only evaluated the relationship between 
the RS and clinical result of ER-positive, node-negative early 
breast cancer, but also explored the prognostic ability in late 
recurrence of breast cancer. The 10-year distant recurrence 
rates among low-, intermediate- and high-risk groups were 
6.8%, 14.3% and 30.5%, respectively. It showed that the RS 
was related to distant relapse in patients without adjuvant 
chemotherapy, regardless of age and tumor size and performed 
better than both of them (P < 0.001). A summary of key studies 
can be found in Table 1 [3, 5-13].
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The Clinical Utility of Oncotype DX (RS)
RS can predict chemotherapy sensitivity in patients with ER-
positive, node-negative breast cancer. Paik et al [5] studied 651 
cases of breast cancer who were enrolled in NSABP B-20 and 
randomly assigned them into a TAM group and a TAM combined 
with chemotherapy group (chemotherapy regimen for CMF or 
MF regimen, TAM + CMF/MF group). The 10-year follow-up 
results showed that patients with high RS had benefited from 
cytotoxic chemotherapy, with the 10-year metastasis rate being 
decreased by 27.6%. In contrast, the 10-year distant metastasis 
rate was decreased by an average of -1.1% in patients with low 
RS who received adjuvant chemotherapy. Therefore, patients 
with ER-positive early breast cancer and high RS should benefit 
from chemotherapy, whilst patients with low RS cannot. RS can 
help select patients who experience little benefit of chemothera-
py and can avoid the toxic effects of chemotherapy.
In a phase III trial, the Trial Assigning Individualized Op-
tions for Treatment (TAILORx), there was a prospective phase 
to further validate the function of RS in patients with hormone-
receptor (HR)-positive, HER2-negative, node-negative breast 
cancer. The results from TAILORx indicated that patients with 
very low RS results (< 11) had excellent clinical outcome with 
a rate of 5-year freedom from distant recurrence with endocrine 
therapy at 99.3% and a rate of overall survival (OS) of 98.0%, 
even without chemotherapy [6]. As for its excellent utility in 
identifying patients with good outcome, Oncotype DX RS be-
came the only gene-expression assay that was recommended at 
level I evidence in the AJCC Prognostic Stage Group.
In patients with HR-positive, node-negative breast can-
cer, the RS showed excellent clinical utility to predict clini-
cal outcomes. The Southwest Oncology Group (SWOG)-8814 
focused on exploring the benefit of therapy in patients with 
HR-positive, node-positive breast cancer. It enrolled post-
menopausal women treated with chemotherapy or simple en-
docrine adjuvant therapy, of which 367 cases (40%) received 
an RS detection. The results showed that RS had a definite 
predictive value (P = 0.016) for adjuvant treatment benefit 
over 5 years and was poorly predicted for treatment beyond 
5 years (P = 0.87). High-risk patients receiving chemotherapy 
combined with endocrine therapy compared with simple en-
docrine therapy benefit significantly (P = 0.033). SWOG-8814 
trial showed that the RS was also prognostic for TAM-treated 
patients with positive nodes and predicts significant benefit of 
chemotherapy (CMF) in tumors with a high RS [7].
ECOG E2197 also studied the predictive utility of RS on 
loco-regional recurrence (LRR) in 388 lumpectomy patients 
with 0 - 3 positive nodes treated with chemo-endocrine therapy 
and breast radiology. With 9.7 years median follow-up, the 10-
year rates of LRR for HR-positive tumors were 3.8%, 5.1% 
and 12.0% for low, intermediate and high risk of RS (P = 0.12) 
[14]. Similarly, in NSABP B-28, which compared the benefit 
to patients from chemotherapy and endocrine therapy, RS was 
a statistically predictor of LRR, with 10-year cumulative inci-
dence of LRR of 3.3%, 7.2% and 12.2% in low, intermediate 
and high RS (P < 0.001) [8]. RS is a strongly predictive fac-
tor of LRR for HR-positive breast cancer regardless of node 
status. Another study, PACS 01 trial ,with a median of 7.7 
years follow-up, showed that RS was a significant predictor of 
DRFIS, DFS and OS (P < 0.001) in HR-positive, node-positive 
patients treated with chemotherapy plus endocrine therapy [9].
In a recent prospective phase III trial, West German Study 
Group Plan B, 348 patients (15.8%) with RS ≤ 11 had excellent 
3-year survival even if they omitted chemotherapy. The 3-year 
DFS in patients with RS ≤ 11 was 98%, in which 41.1% had 
node-positive and 32.5% were grade 3 disease. These were the 
first prospective data to report clinical outcome when RS was 
used to make physical decision in patients with HR-positive 
breast cancer regardless of lymph node invasion [10].
Another ongoing multicenter phase III trial, RxPONDER 
trial (Rx for Positive Node, Endocrine Responsive Breast Can-
cer) revealed that patients with node positive breast cancer who 
had low to intermediate RS results could benefit from chemo-
therapy [11]. The trial also determined whether there is an op-
timal RS cutoff for these patients above which chemotherapy 
should be recommended in clinical practice. RxPONDER trial 
randomized patients with HR-positive, HER2-negative and 1 - 
3 lymph nodes breast cancer with RS ≤ 25, to improve the risk 
of stratification in patients with low or intermediate RS.
MammaPrint
MammaPrint was first developed by the Netherlands Cancer 
Institute group. Van’t Veer et al [15] used a gene-expression 
panel to detect 78 frozen tumor tissues from patients with pT1-
2cN0 invasive breast carcinoma who had received standard 
treatment. Ribonucleic acid (RNA) was isolated from fresh 
frozen tumor tissue to obtain complementary DNA (cDNA). 
The gene-expression panel contains 70 genes related to early 
risk of metastasis, including tumor invasion, metastasis, inter-
stitial invasion, and angiogenesis-related genes. A total of 295 
patients under 53 years old were enrolled in the study. The pa-
tient had tumors that were of different tumor types as assessed 
using immunohistochemistry results and lymph node status. 
All the patients were assessed to follow up for at least 5 years. 
From the gene expression, patients were divided into good 
prognosis signature and poor prognosis signature. The results 
showed risk of 10-year distant metastasis in patients of poor-
prognosis signature was significantly higher than that in good-
prognosis signature (85% versus 51%, P < 0.001) and overall 
10-year survival was 95% versus 55% in these two groups. 
Compared with histological grade, primary tumor size, vas-
cular invasion, hormone receptor status and other adverse fac-
tors, the 70-gene panel was the strongest predictor of disease 
progression [16]. In addition, patients in the poor-prognosis 
group who received chemotherapy had a significantly reduced 
10-year distant metastasis rate (HR 0.37, P < 0.001). There-
fore, it is recommended that patients with poor-prognosis sig-
nature receive cytotoxic adjuvant chemotherapy in order to 
reduce the risk of distant metastasis [12].
The Clinical Utility of MammaPrint
The microarray-prognostics-in-breast-cancer (RASTER) trial 
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was the first prospective phase III clinical trial to investigate 
the prognostic value of the 70-gene signature for distant re-
currence in patients with breast cancer and also compared the 
70-gene signature with the Adjuvant! Online (AOL). A total of 
427 cases of cT1-3N0M0 breast cancer patients were enrolled. 
Both the 70-gene expression and AOL were taken into consid-
eration whilst making adjuvant systemic treatment decision. 
With a median follow-up of 61.6 months, 5-year DRFI prob-
abilities for 70-gene signature low-risk AOL high-risk patients 
were 98.4%, in which 76% had not received adjuvant chemo-
therapy. The results indicated that the 70-gene signature low-
risk predicted low-risk rate in 5-year distant metastasis/good 
clinical result regardless of AOL score. Compared with AOL, 
the 70-gene signature is more valuable for patients with good 
clinical outcome [17].
Other studies aiming at investigating MammaPrint vali-
dation in patients with node-positive breast cancer have been 
conducted. Mook et al [18] further investigated whether the 70-
gene prognosis signature could predict the clinical outcome for 
breast cancer patients with lymph node invasion. Two hundred 
forty-one patients with T1-3N1M0 breast cancer were selected 
to conduct the 70-gene signature and received standard treat-
ment including surgery followed by systemic adjuvant therapy 
and radiotherapy. Ninty-nine patients (41%) were assigned to 
the good-prognosis group, and 142 cases (59%) to the poor-
diagnosis group. The rates of 10-year distant metastasis-free 
survival and breast cancer specific survival were significantly 
higher in the good-prognosis group than the poor-prognosis 
group (91% versus 76%, 96% versus 76%). The results of mul-
tivariate analysis suggested that the predictive value of the 70-
gene prognosis signature was significantly superior to lymph 
node invasion, histological grade and ER status in predicting 
breast cancer outcome. It is suggested that the 70-gene progno-
sis signature can predict the disease outcome in patients with 
node-positive breast cancer.
A randomized prospective trial, the MINDACT study, re-
cently further confirmed the clinical utility of MammaPrint. 
MINDACT involved 6,693 new diagnosed breast cancer pa-
tients with 0 - 3 metastatic lymph nodes [19]. After 5 years me-
dian follow-up, the study demonstrated excellent clinical out-
comes in patients at high clinical risk but with low genomic risk 
even omitting chemotherapy. Of all patients with breast cancer 
at the highest clinical risk, 46% were categorized as being low 
genomic risk. The distant metastasis-free survival was 94.7% 
in these patients at low genomic risk without chemotherapy, 
1.5% age points lower compared to patients treated with chem-
otherapy. This indicated that 46% of patients with breast cancer 
at a high clinical risk might not require chemotherapy because 
of low risk as evaluated by MammaPrint. The 70-gene progno-
sis signature outperforms traditional prognostic factors in pre-
dicting disease outcome in patients with 0 - 3 positive nodes. 
Moreover, the signature can accurately identify patients with an 
excellent disease outcome in patients who may be safely spared 
adjuvant chemotherapy. For this reason, EGTM (The European 
Group on Tumour Markers) recommended MammaPrint to be 
used for determining prognosis and guiding decision-making 
with respect to the administration of adjuvant chemotherapy 
in patients with newly diagnosed invasive breast cancer that 
is lymph node negative or 1- 3 lymph node positive. Patients 
with high clinical risk but low risk based on MammaPrint can 
avoid adjuvant chemotherapy [20]. MammaPrint also became 
the first assay to be cleared at the 510(k) level approved by the 
US FDA [21], used to predict the clinical outcome of women 
under the age of 61 years with ER-positive or negative, lymph 
node-negative breast cancer [22].
Relationship Among Different Gene Panels
Fan et al [23] compared the prognostic value of five gene-
expression panels including intrinsic subtypes, the 70-gene 
prognosis signature (MammaPrint), wound response, RS (On-
cotype Dx) and the two-gene ratio. The models based on in-
trinsic subtypes, the 70-gene signature, wound response and 
RS were significant predictors of relapse-free survival and OS. 
They then compared RS and MammaPrint in a group of 295 
patients, considering low and intermediate RS with good-prog-
nosis signature in the 70-gene signature. Eighty-one percent of 
samples agreed in the two models, especially in patients with 
good clinical outcome. In addition, HER2+ and ER-negative 
subtype and poor-outcome luminal B subtype were likely to 
be in the poor-prognosis groups in both of 70-gene prognosis 
signature and RS. After that trial, Prat et al [24] compared the 
prognostic value of the PAM50 intrinsic subtyping and risk 
of RS, the 70-gene signature, relapse (PAM50-ROR) score, 
Rotterdam 76 gene and the index of sensitivity to endocrine 
therapy (SET) in 594 patients who received local treatment 
and TAM only. The result confirmed that RS and the 70-gene 
prognosis signature were highly prognostic in breast cancer 
patients in disease relapse risk from the genetic level, whilst 
instinct subtypes distinguish patients of different risk from 
molecular or protein expression level. Although the genes de-
tected and the techniques differ between RS and MammaPrint, 
both of the two gene panels are proved to be consistent with 
long-term clinical outcome, especially accurately identifying 
breast cancer patients with a low risk of recurrence who are 
predicted to derive minimal benefit from chemotherapy.
Present and Prospective for Multigene Panels
In the last decade, clinicians and researchers have been dedi-
cated in trying to solve how to avoid under and overtreatment 
in patients with curable breast cancer. The ability to personal-
ize treatment based on tumor biology and to reduce unneces-
sary chemotherapy is the key to optimizing patient care. Gene 
panels have proved to be promising tumor markers in predict-
ing disease progress and making personalized physical deci-
sion [25]. After TAILORx and many other prospective trials, 
RS and the 70-gene prognosis signature have been proved to 
have clinical relevance with disease outcome. The two gene 
panels are most well validated and used in the clinical setting 
to assist in treatment decisions for patients with HR-positive 
early stage breast cancer.
Many international guidelines have affirmed the clinical 
utility of gene panels. These studies were discussed in the re-
cent St Gallen International Expert Panel Meetings (2017) on 
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the primary therapy of early breast cancer, seeking consensus 
as to the instances that multigene panels could be used to assist 
physician decision. The majority of the panel agreed that for 
patients with ER+, HER2- breast cancer, clinically valuable in-
formation on prognosis and risk helping to omit chemotherapy 
may be provided by RS and MammaPrint both in patients of 
node-negative or positive breast cancer. Both Oncotype DX 
and MammaPrint can predict distant recurrence in at least 5 
years; however, the efficacy of multigene panels in predicting 
relapse rates in HR-positive disease beyond 5 years remains to 
be confirmed by further studies.
The current use of multigene panels in clinical practice 
does reflect a personalized clinical decision-making progress. 
Although the cost of RS and the 70-gene prognosis signature 
is currently $3,460 and $4,250, respectively, a number of retro-
spective studies have confirmed the cost-effectiveness of gene 
panels in treatment decision-making of breast cancer. Each 
patient benefits from £3,000 to £40,000 per quality-adjusted 
life year, indicating that the application of gene panels in clini-
cal practice avoids overtreatment as well as reducing treatment 
cost [26, 27]. Loncaster et al [28] evaluated the impact of RS 
on adjuvant chemotherapy decision-making in clinical prac-
tice in patients with early curable breast cancer and showed 
that 60.3% of ER+, HER2-, node-negative patients were spared 
chemotherapy due to low RS. Even in node-positive patients, 
many avoided adjuvant chemotherapy as well. A meta-analysis 
containing 2,229 patients showed 29.52% treatment decisions 
on chemotherapy changed due to the use of RS, of which 12% 
are reduction of chemotherapy [29]. Similarly, Exner et al [30] 
reported that decision changes were recorded in 18.6% cases 
and that two-thirds of patients can be spared chemotherapy 
due to the use of MammaPrint. The routine use of multigene 
panels in early breast cancer has significant cost saving [25]. 
Currently, RS is recommended in patients with ER+, HER2-, 
T > 0.5 cm early breast cancer by the National Comprehen-
sive Cancer Network (NCCN), the European Society for 
Medical Oncology (ESMO) ,the American Society of Clini-
cal Oncology (ASCO), the St Gallen Group and the EGTM, 
Arbeitsgemeinschaft Gynakologische Onkologie (AGO) for 
use in selected patients [1, 20, 27, 28, 31, 32]. It is also recom-
mended for patients with node-positive breast cancer using the 
guidelines above, except the ASCO guideline. MammaPrint is 
recommended for patients with node-positive breast cancer in 
ESMO, St Gallen and EGTM, but not in ASCO and NCCN 
guideline [20].
Due to the multigene panel including genes related to bio-
logical behavior such as cancer metastasis and invasion, the 
clinical utility of multigene panels will be expanded as studies 
continue. Jegadeesh et al found RS > 24 was related with LRR 
in patients who received mastectomy and that the 5-year LRR 
rate was 27.3% versus 10.7% in patients of RS ≤ 24, indicat-
ing patients with RS > 24 may benefit from post-mastectomy 
[33]. The recently published report from the NSABP B-28 
also showed that RS was a strong predictive factor of LRR 
in ER-positive, node-positive breast cancer after treatment; 
the final result will reveal how RS helps in selecting patients 
for comprehensive radiology, which may broaden the clinical 
utility of RS [34]. Similarly to NSABP B-28, MINDACT has 
more broadly represent women with breast cancer than other 
studies with MammaPrint. In MINDACT, 10% of enrolled pa-
tients were HER2-positive, 12% were HR-negative, and 20% 
had 1 - 3 positive nodes. The result of MINDACT can perhaps 
broaden the clinical utility of MammaPrint if the genetic tumor 
screening is able to find out who requires chemotherapy and 
who does not [35].
Limitation of Multigene Panels
The multigene panels represent a conceptual advance over ar-
bitrary groupings based on traditional clinicopathlogical fac-
tors [36]. Studies on gene panels show a promising future for 
clinical use, although some limitations hinder the techniques 
from wider use. One such limitation is that the cutoff for gene 
panels varies between studies. The consistent findings of large 
prospective clinical trials further validate the clinical utility of 
the RS and strongly suggest that adjuvant chemotherapy may 
be spared for patients with very low (< 10) RS results [37]. 
We are seeking consensus on the evidence and opinions re-
garding correct cutoff points and how to deal with patients of 
intermediate risk identified by the RS. As Jiang, a member of 
the 15th St Gallen consensus panels mentioned in the voting 
session: if we use multigene assays in clinical practice, the first 
thing is to clearly understand how high the genomic score or 
risk is high. Another limitation is that MammaPrint requires 
freshly frozen tissue collected into an RNA preservative so-
lution, which makes it more complex to conduct than other 
panels. Otherwise, disparities in access to genomic diagnostic 
test in some area or race also make it difficult to maximum the 
clinical utility of gene panels [38, 39].
Conclusion
Multigene panels can provide better risk discrimination relative 
to clinicopathological factors, which are significantly superior 
to traditional prognostic factors in predicting clinical outcome 
and identifying patients who can be spared chemotherapy 
safely. Available evidence supports the clinical validation of 
multigene panels and that they are proved to be cost saving 
while assisting treatment decision. Oncotype DX and Mam-
maPrint have the strongest evidence supporting their clinical 
utility and decision effectiveness, and have been widely used 
in luminal type breast cancer [40]. The AJCC Prognostic Stage 
Group containing multigene panels will be globally used from 
January 1, 2018. It suggests that prognostic stage grouping 
should be used in countries where biomarker tests are routinely 
performed, indicating that multigene molecular profiling will 
become part of cancer stage evaluation, and will need to be 
taken into consideration when making clinical decisions [2]. 
The future of multigene panels is promising in personalizing 
treatment as more studies continue. However, many issues re-
main to be solved before multigene panels have a wider influ-
ence on breast cancer treatment. Importantly new issues, such 
as how to accurately predicate late recurrence in ER-positive 
cancer and how to provide more access to multigene panels, 
should be solved in the future.
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